MedTrace Logo

A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors

NCT06063681 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2025-06-08

No results posted yet for this study

Summary

This is an open-label, dose-escalation, multi-center phase 1 study evaluating the safety, tolerability, and pharmacokinetics (PK) of SR-8541A administered orally as a monotherapy or in combination with an immune checkpoint inhibitor (ICI) in subjects with solid tumors.

Conditions

  • Advanced / Metastatic Solid Tumor

Interventions

DRUG

SR-8541A

orally administered ENPP1 inhibitor

DRUG

Immune checkpoint inhibitor (ICI)

The ICI will be either nivolumab or pembrolizumab.

Sponsors & Collaborators

  • Stingray Therapeutics

    lead INDUSTRY

Principal Investigators

  • Vinod Ganju, MD · Peninsula & South Eastern Haematology & Oncology Group

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-12
Primary Completion
2025-12-31
Completion
2025-12-31
FDA Drug
Yes

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06063681 on ClinicalTrials.gov